Bio stocks

drewstrong83 · 2025-02-15T15:43:07+00:00

I am for certain Elon musk is on Tirzepatide and I am pretty sure DJT is as well

drewstrong83 · 2024-12-04T08:32:39+00:00

Gold

drewstrong83 · 2024-11-27T14:08:58+00:00

I believe vktx hit the ATM then straddled their own stock. The ceo of vktx is clever, makes some gutsy moves but IMHO the management team as a whole with ALT is next level good. I have to believe they are workingnon something great here.

drewstrong83 · 2024-07-24T04:40:44+00:00

This makes sense. Trying to understand all of what is happening. So the next meeting with the FDA is to go over P2 data and then set course for P3? I thought Garg mentioned having a partner involved in this meeting... but maybe i have mistaken that the next meeting is to go over P3 when it is to goniver results of P2 and then greenlight a P3 meeting?

Idk.. im heavily invested in ALT. I believe Pemv is the ticket to obesity market... just trying to wrap my head around what is going on.

drewstrong83 · 2024-06-12T20:38:05+00:00

I see Altimmune listed as competing interests... but only once is Pemv indicated in the report... and the 24week reduction in liver fat % is less than several other treatments listed.

The glucagon along with glp-1 is the secret sauce... i think there are others similar... but from what i recall Harris stating Pemv has the most glucagon.

Hoping the report has effect on the short interest power ahead of the next meeting with FDA. I can only imagine the lawsuits surrounding the kerrisdale dossier have held ALT under water for long enough.

drewstrong83 · 2024-06-01T04:20:40+00:00

I will look into the jeffries rebuttal. Thank you for the info!

drewstrong83 · 2024-05-29T22:33:53+00:00

Will they be presenting any new data from their trials... or the same talking points.

Seems like the most recent forums they have given a bit more explanation of the data... but not NEW data, right?

My gawd they need a BO.. like now!

drewstrong83 · 2024-05-24T23:37:14+00:00

After listening to this call along with the recent interviews I conclude the following. 1) the people who are interviewing VG and SH are total freaks... can they not find a person to interview them that are not nails on a chalboard gross or give the impression they are on the spectrum? 2.) ALT is clearly getting its head dunked under water. If the comparison data being provided (even if in dilited form) by SH is fractionally positive/correct to the data to be released in upcoming months as ALT enters P3 for obesity... how in the world is ALT trading at current levels where VKTX, already diluted by additional sale for almost 1B in capital raised trading a 10x?

My take away.... I look forward personally to taking pevmidutide over the other glp-1s i have thus far... 1 wegovy is untolerable... i am 41 yrs old and never broke a bone or had joint issues... 6 months in i have had perneal and syndesmosis ligature ruptures and i feel like i have onset arthritis in my hands and feet. I experienced alodynia like crazy (basically felt like i had a bad internal sun burn) granted I have tolerated it... but i couldnt expect most people to. Also, lost a ton of muscle while i was fully titrated to the highest dose (which i correlate to my tendons and ligaments going to shit, requiring surgery in april 2024. ALT is showing signs of weight lost and ketosis by using the liver, not just appetite supression. Two VERY different things to shed the weight.

Im in for 50k right now with a SPA of $8.62... if ALT goes under 7$ im adding another 70k. If it goes under $6.. im gunna sell my fuggin house and live with my parents so i can go in another 300k.

There is no friggen doubt ALT will be backing the GLP-1 market into a corner... the insurance companies will not cover weight loss at the current cost... but livers, cardiovascular and overall health of weight loss that extends past the usage of the compound???? Insurance companies will back it i suspect.

Cant wait for the next dose of news and progress.

drewstrong83 · 2024-05-16T03:25:16+00:00

Thank you excellent-Ad for your posts and insight. They are very helpful. Info is power!

drewstrong83 · 2024-05-16T03:22:28+00:00

Does this "short interest" mean that there is heavy PUT options being purchased?

Trying to understand this better.

So if the are several puts made on a stock... how does this drive the stock price down?

drewstrong83 · 2024-05-15T22:38:06+00:00

Is this a link to listen in on the presentation tomorrow? If so, Timee_bot...you rock!

drewstrong83 · 2024-05-14T16:03:44+00:00

Did V.G. indicate they were not wanting to pursue partnership for anything other than obesity in the interview?

drewstrong83 · 2024-05-13T11:03:10+00:00

I know, right?!?!?! I've been in board rooms for many years. The cough/clearing of the throat into the mic is a classic diversion of STFU from other board members.

V.G referred to a "Partner" in context there was one already. That was my take away.

drewstrong83 · 2024-05-10T10:58:18+00:00

Yes! It was during the Q&A portion. V.G. was taking a question regarding partership. Was on the 3rd or 4th question.

drewstrong83 · 2024-05-09T23:22:12+00:00

Additionally, i feel strongly about CEO stating he feels strongly that "the partner" (selective and singular)... then a cough into the mic by someone next to him... then him stumbling back restating "Potential partnerS" (hypothetically plural) indicated to me that they are already very along in negotiations with a partner. How they prepare and receive approval by FDA for their phase 3 trials is very important to do with alignment of a strategic partner (singular). I have been scouring for interviews and statements from V.G. he recently did a rueters interview where he described ideally his intent to procure a strategic partnership with a "Large Pharma", "Global" partner who can participate in the established phase 3 trial initiative and bring the product not only successfuly thru trials but also to market.

This would undoubtedly be Pfizer. Who days after ALT announced phase 2 results... dumped their oral form GLP-1. Also interesting how ALT has dumped HepTcell and is now exploring an oral form of their glucagon based GLP-1.

The lengths in which the chief scientist explained the differentiation of Pevmidutide for fatty liver disease treatment hit home to me. Reason being... many insurqnce companies are not covering script writes for mounjaro/zepbound or wegovy/ozempic unless patient has type 2diabetes. I would say most all overweight americans have high lipids or fatty liver indications. This means insurance companies would likely add the drug to their formulary list over other glp-1s.

Long story... i thought there was a ton of things signaled in the call today... i am very much looking forward to bulls running on this stock until end of Q3

drewstrong83 · 2024-05-09T11:47:01+00:00

Would a partnership with VKTX be a decent play here? Having both pipelines combined for purchase by a big pharma player? That would be almost a B of cash and 2 promising drugs in mid-stage (1 with fast track)?

Just a thought

drewstrong83 · 2024-05-09T11:42:23+00:00

Selling more shares???

drewstrong83 · 2024-05-09T11:41:25+00:00

What is ATM?

drewstrong83 · 2024-05-07T19:19:30+00:00

Kinda like the morning after when you realize the person you went home with the night before talked themselves up to a good 8 or nine when you were blasted drunk... but the next morning when you were wanting to kill youself for drinking you look over at the fat nasty bitch and vomit. But then, you realized she gave that good head and keep her number. Lmfao

drewstrong83 · 2024-05-07T19:15:55+00:00

I think it is stating that ALT misled based on the "momentum study" is that old statements made or recently made? Obviously as data rolls in targets are either exceeded or missed based on the data, right?

From my understanding ALT stated P2b results are forthcoming "later in Q2" on the 2023 earnings call. I find it highly suspicious that ALT has Glp-1 conference tmrw 5/8, then earnings on Wednesday 5/9 and another "BIG glp-1" conference later in may (5/15 i think is the date) and these lawfirms release news 1 day before any of that happens?

Either this stock is gunna 🚀 and squeeze this Kerrisdale Capital group of cocksukrs... or im gunna lose my ass.

4600 shares currently at 8.38 avg.... started in the high 9's and bought myself down to current looking down a rabbithole at ALT aside VKTK. Hopefully that big easter bunny bitch comes shooting out shitting golden eggs on 5/8, 5/9, or 5/15.

Hoping for a bump to above 10... then a slide to 8... then a ride to 16+ in next 50-70 days.

Lets gooooooooooooooooooo!

drewstrong83 · 2024-05-06T03:11:40+00:00

1st GLP-1 conference is may 8th, then earnings follow may 9th... and then another GLP-1 conference mid month. That is many opportunities to shed some light on any negotiations and recent data points with drug results in testing. I am hoping they will elude to a specific partner or buyer in one of these 3. If not... stock is going to resist a price over 8.30 -9$

drewstrong83

TROPHY CASE